Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122090964 | 12209096 | 4 | F | 2013 | 20160803 | 20160324 | 20160805 | EXP | US-PFIZER INC-2016172106 | PFIZER | 61.00 | YR | F | Y | 122.45000 | KG | 20160805 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122090964 | 12209096 | 1 | PS | SILDENAFIL CITRATE. | SILDENAFIL CITRATE | 1 | Oral | 20 MG, 3X/DAY | A562401 | 21845 | 20 | MG | FILM-COATED TABLET | TID | |||||
| 122090964 | 12209096 | 2 | SS | SILDENAFIL CITRATE. | SILDENAFIL CITRATE | 1 | 21845 | FILM-COATED TABLET | |||||||||||
| 122090964 | 12209096 | 3 | SS | SILDENAFIL CITRATE. | SILDENAFIL CITRATE | 1 | 21845 | FILM-COATED TABLET | |||||||||||
| 122090964 | 12209096 | 4 | SS | REVATIO | SILDENAFIL CITRATE | 1 | 20 MG, 3X/DAY | A563501 | 21845 | 20 | MG | FILM-COATED TABLET | TID | ||||||
| 122090964 | 12209096 | 5 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | UNK | Y | 0 | ||||||||||
| 122090964 | 12209096 | 6 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Y | 0 | |||||||||||
| 122090964 | 12209096 | 7 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Y | 0 | |||||||||||
| 122090964 | 12209096 | 8 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Y | 0 | |||||||||||
| 122090964 | 12209096 | 9 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Y | 0 | |||||||||||
| 122090964 | 12209096 | 10 | C | OXYGEN. | OXYGEN | 1 | UNK (1 1/2 TO 2 HRS. 24 HRS) | 0 | |||||||||||
| 122090964 | 12209096 | 11 | C | GLIPIZIDE ER | GLIPIZIDE | 1 | 5 MG, 1X/DAY, (1 A DAY IN THE AM) | 0 | 5 | MG | TABLET | QD | |||||||
| 122090964 | 12209096 | 12 | C | POTASSIUM | POTASSIUM | 1 | 10 MG, 2X/DAY | 0 | 10 | MG | BID | ||||||||
| 122090964 | 12209096 | 13 | C | METOPROLOL. | METOPROLOL | 1 | 25 MG, 2X/DAY | 0 | 25 | MG | BID | ||||||||
| 122090964 | 12209096 | 14 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 1000 MG, 2X/DAY, 500 MG, 2 TABS TWICE A DAY | 0 | 1000 | MG | TABLET | BID | |||||||
| 122090964 | 12209096 | 15 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | 40 MG, 1X/DAY (AT NIGHT) | 0 | 40 | MG | TABLET | QD | |||||||
| 122090964 | 12209096 | 16 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 40 MG, AS NEEDED (1 A DAY AS NEEDED) | 0 | 40 | MG | |||||||||
| 122090964 | 12209096 | 17 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 40 MG, UNK (2X0.5 DAY) | 0 | 40 | MG | |||||||||
| 122090964 | 12209096 | 18 | C | BAYER ASPIRIN | ASPIRIN | 1 | 81 MG, 1X/DAY | 0 | 81 | MG | QD | ||||||||
| 122090964 | 12209096 | 19 | C | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | 25 MG, UNK (2X0.5 DAY) | 0 | 25 | MG | TABLET | ||||||||
| 122090964 | 12209096 | 20 | C | POTASSIUM CL | POTASSIUM CHLORIDE | 1 | 10 MG, 1X/DAY | 0 | 10 | MG | QD | ||||||||
| 122090964 | 12209096 | 21 | C | METFORMIN HCL | METFORMIN HYDROCHLORIDE | 1 | 100 MG, 2X/DAY | 0 | 100 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122090964 | 12209096 | 1 | Pulmonary hypertension |
| 122090964 | 12209096 | 2 | Pulmonary arterial hypertension |
| 122090964 | 12209096 | 3 | Arterial disorder |
| 122090964 | 12209096 | 4 | Pulmonary arterial hypertension |
| 122090964 | 12209096 | 5 | Hypertension |
| 122090964 | 12209096 | 6 | Anticoagulant therapy |
| 122090964 | 12209096 | 7 | Cardiac failure congestive |
| 122090964 | 12209096 | 8 | Pulmonary hypertension |
| 122090964 | 12209096 | 9 | Arterial disorder |
| 122090964 | 12209096 | 10 | Pulmonary arterial hypertension |
| 122090964 | 12209096 | 11 | Diabetes mellitus |
| 122090964 | 12209096 | 12 | Mineral supplementation |
| 122090964 | 12209096 | 13 | Hypertension |
| 122090964 | 12209096 | 14 | Diabetes mellitus |
| 122090964 | 12209096 | 15 | Blood cholesterol increased |
| 122090964 | 12209096 | 16 | Fluid retention |
| 122090964 | 12209096 | 18 | Cardiac disorder |
| 122090964 | 12209096 | 19 | Hypertension |
| 122090964 | 12209096 | 21 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122090964 | 12209096 | OT |
| 122090964 | 12209096 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122090964 | 12209096 | Epistaxis | |
| 122090964 | 12209096 | Myocardial infarction | |
| 122090964 | 12209096 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122090964 | 12209096 | 1 | 2013 | 0 | ||
| 122090964 | 12209096 | 4 | 2012 | 0 | ||
| 122090964 | 12209096 | 5 | 2009 | 201602 | 0 | |
| 122090964 | 12209096 | 10 | 2011 | 0 | ||
| 122090964 | 12209096 | 11 | 2014 | 0 | ||
| 122090964 | 12209096 | 12 | 2012 | 0 | ||
| 122090964 | 12209096 | 13 | 2013 | 0 | ||
| 122090964 | 12209096 | 14 | 2012 | 0 | ||
| 122090964 | 12209096 | 15 | 2015 | 0 | ||
| 122090964 | 12209096 | 16 | 2011 | 0 | ||
| 122090964 | 12209096 | 17 | 2013 | 0 | ||
| 122090964 | 12209096 | 18 | 200303 | 0 | ||
| 122090964 | 12209096 | 21 | 2014 | 0 |